Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) has issued an update.
On September 25, 2025, Evaxion Biotech A/S sold 1,018,000 American Depositary Shares (ADSs) in an at-the-market offering, generating approximately $4.3 million in proceeds. The company’s share capital increased significantly, with amendments to the Articles of Association reflecting these changes. Between October 3 and October 10, 2025, further share capital increases occurred due to the exercise of investor warrants, raising additional funds and expanding the company’s capital base. These financial activities are part of Evaxion’s strategic efforts to bolster its market position and operational capabilities.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its financial challenges, despite strong revenue growth and positive developments in R&D and partnerships. The technical analysis suggests neutral momentum, while valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with financial stability and strategic progress, but regulatory and market challenges remain significant risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion Biotech A/S is a company based in Denmark that specializes in creating advanced software for the development of novel immune therapies and vaccines.
Average Trading Volume: 1,528,374
Technical Sentiment Signal: Hold
Current Market Cap: $60.64M
Find detailed analytics on EVAX stock on TipRanks’ Stock Analysis page.